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Toll-Like Receptor 4 Is Involved in Human and Mouse Vein
Graft Remodeling, and Local Gene Silencing Reduces Vein
Graft Disease in Hypercholesterolemic APOE*3Leiden Mice
Jacco C. Karper, Margreet R. de Vries, Ben T. van den Brand, Imo E. Hoefer, Jens W. Fischer,
J. Wouter Jukema, Hans W.M. Niessen, Paul H.A. Quax
Objective—The goal of this study was to explore the role of Toll-like receptor 4 (TLR4) in vein graft remodeling and
disease.
Methods and Results—First, expression of TLR4 was analyzed in freshly isolated human saphenous veins (huSV), in
freshly isolated huSV ex vivo perfused in an extracorporeal circulation, or in huSV used as coronary vein grafts. Marked
induction of focal TLR4 expression was observed in perfused fresh huSV. Moreover, TLR4 was abundantly present in
lesions in fresh huSV or in intimal hyperplasia in coronary vein grafts. Second, mouse venous bypass grafting was
performed. In grafts of hypercholesterolemic APOE*3Leiden mice, increased TLR4 mRNA and protein was detected
over time by reverse transcription–polymerase chain reaction and immunohistochemistry. Furthermore, the local
presence of the endogenous TLR4 ligands heat shock protein 60, high-mobility group box 1, tenascin-C, and biglycan
in the grafts was demonstrated. TLR4 deficiency in C3H-Tlr4LPS-d (LPS indicates lipopolysaccharide) mice resulted in
4812% less vein graft wall thickening (P0.04) than in Balb/c controls. Moreover, local TLR4 gene silencing in
hypercholesterolemic APOE*3Leiden mice using lentiviral short hairpin RNA against TLR4 administered perivascu-
larly around vein grafts led to a 4413% reduction of vessel wall thickening compared with controls (P0.0059).
Conclusion—These results indicate that TLR4 is involved in vein graft remodeling and can be used as a local therapeutic
target against vein graft disease. (Arterioscler Thromb Vasc Biol. 2011;31:1033-1040.)
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Vein grafts are important conduits for revascularizationduring both coronary and peripheral bypass surgery,
although vein grafts sometimes have poor long-term patency.
Early graft failure is usually due to thrombosis, but long-term
graft failure is caused by vein graft disease (VGD) induced by
wall thickening due to intimal hyperplasia that is triggered by
inflammation. Vein graft wall thickening is in part character-
ized by smooth muscle cell (SMC) proliferation, matrix
turnover, and an influx of lipids and inflammatory cells.1,2
The innate immune system contains multiple receptors that
recognize a broad variety of molecular structures. Toll-like
receptors (TLRs) have a key role in driving inflammation
regulating the innate response after binding pathogen-
associated molecular patterns or damage-associated molecu-
lar patterns (DAMPs), respectively.3–7 TLR4 is a membrane-
bound receptor located on a variety of immune and
nonimmune cells, including macrophages, endothelial, and
SMCs. Cell stress and tissue damage may cause a release of
DAMPs that function as endogenous TLR4 ligands and lead
to activation and upregulation of the expression of TLR4,
resulting in a proinflammatory response.6,8–10 The role of
TLR4 in vascular remodeling, especially arterial remodeling,
has previously been demonstrated in various studies either
directed at atherogenesis and plaque (de)stabilization or
directed at the role of TLR4 in postinterventional arterial
remodeling after angioplasty.11–16 However, the role of TLR4
and its endogenous ligands in remodeling of venous segments
(eg, in vein graft remodeling) is still unknown. Furthermore,
it has been suggested that unactivated arterial vascular
smooth muscle cells (VSMC) do not express TLR4 and that
TLRs may have a vessel-specific profile that may also vary
because of changes in cellular activation, differentiation, and
other local processes.17 Interestingly, nonactivated VSMC
from huSV do express TLR4.18
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To modulate atherosclerotic plaque formation by interfer-
ing in the TLR4 pathway, systemic therapeutic interventions
would be required. However, because of the important role of
the TLR4 pathway in the host defense mechanism, such a
systemic approach would be undesirable. In contrast, venous
bypass grafts do permit local therapeutic interventions. From
the point of therapeutic interventions in the TLR4 pathway
to reduce vascular remodeling VGD is of more interest and
has more potential. Local therapy against VGD can be
done easily, for example, by topical inhibitor application to
the adventitial layer, because adventitial cells contribute
extensively to proliferation and migration of SMC and
subsequent vein graft remodeling.19 –23 Therefore, local
gene transfer to silence TLR4 expression would be an
interesting approach for therapy to improve graft survival,
once the role of TLR4 in VGD has been established.
In the current study, we focus on the role of TLR4 in vein
graft remodeling by illustrating the presence and upregulation of
TLR4 and its endogenous ligands in both human and murine
venous segments used for vein grafting. Moreover, a causal role
of TLR4 was studied by performing vein grafting in TLR4-
deficient mice (C3H-Tlr4LPS-d mice; LPS indicates lipopolysac-
charide) or by local TLR4 gene silencing in murine vein
graft using a lentiviral short hairpin RNA (shRNA) con-
struct against TLR4. The latter study was performed in
hypercholesterolemic APOE*3Leiden mice to mimic the
situation of vein grafting in hypercholesterolemic patients
as closely as possible.
Materials and Methods
For a detailed description of all materials and methods used,
see the supplemental material, available online at http://atvb.
ahajournals.org.
In brief, immunohistochemistry for TLR4 was performed on
paraffin-embedded sections of human saphenous vein (huSV) seg-
ments, freshly isolated, freshly isolated and ex vivo perfused in an
extracorporeal circulation for 4 hours, or used for minimally 5 years
as coronary vein grafts. Also, murine vein graft segments were
analyzed for TLR4 expression and for its endogenous ligands heat
shock protein 60 (HSP60), high-mobility group box 1 (HMGB1),
tenascin-C, and biglycan.
Lentiviral shRNA vectors against murine TLR4 were established
based on the Mission library (Sigma-Aldrich).
Vein grafting in mice was performed by placing a venous
interposition (vena cava) in the carotid artery of either Balb/c mice,
TLR4-deficient (C3H-Tlr4LPS-d) mice, or hypercholesterolemic
APOE*3Leiden mice. In the APOE*3Leiden mice, grafts were
treated locally with the lentiviral short hairpin TLR4 (shTLR4)
construct.
Figure 1. TLR4 expression on cross-sections of huSV. Freshly
harvested huSV stained positive for TLR4 on the circular muscle
layer (A). Preexistent intimal lesions in freshly harvested huSV
showed several TLR4 positive spots (B), and coronary huSV
grafts derived at autopsy showed a profound expression of
TLR4 in the thickened vein graft wall (C). CML indicates circular
muscle layer; LML, longitudinal muscle layer; PIL, preexistent
intimal lesion; TIL, thickened intimal layer.
Figure 2. Freshly isolated huSV was divided into 2 parts. One
part was directly fixated (and paraffin embedded), and the other
part was placed into an extracorporeal circulation system for 4
hours with arterial pressure before fixation. Cross-sections of
both huSV parts were stained for TLR4. The longitudinal muscle
layer of directly fixated huSV showed a few TLR4-positive spots
(A). A rapid increase of TLR4 expression was seen in the longi-
tudinal muscle layer of huSV after 4 hours of perfusion with ar-
terial pressure (B). LML indicates longitudinal muscle layer.
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Results
TLR4 Presence in huSV and Coronary
Vein Grafts
Human vein graft was obtained in the operating room during
coronary artery bypass grafting procedures. One segment was
directly taken for histological and immunohistochemical
examination, and the remaining segment was placed in a
perfusion circuit that was connected to the heart-lung ma-
chine. Samples were perfused with autologous whole blood,
with a pressure of 60 mm Hg (nonpulsatile flow). After 4
hours of perfusion, segments were taken for histological and
immunohistochemical examination. Furthermore, vein grafts
that served as coronary arterial bypass grafts for more than 6
years were derived at autopsy. To study the presence of TLR4
during remodeling in huSV, TLR4 expression was analyzed
in the freshly isolated huSV, in preexisting intimal lesions
within these segments and the coronary vein grafts. In the
fresh huSV, TLR4 expression could be detected, especially in
the circular SMC layer (Figure 1A). Also, the endothelial
layer and adventitial vessels stained positive for TLR4 (not
shown). Some of the venous segments contained spontaneous
lesions, indicated by intimal hyperplasia formation. These
lesions represent a focal area of spontaneous remodeling and
demonstrated a marked presence of TLR4 (Figure 1B). In
addition, a profound TLR4 expression was observed in
severely remodeled coronary vein grafts with a saphenous
vein origin (Figure 1C). These grafts were obtained at
autopsy. They had been in situ for minimally 5 years and are
representative sections of remodeled vein grafts.
Focal TLR4 Expression After Graft Perfusion
In vein grafting, early damage to the vessel wall is initiated
immediately by surgical manipulation and after transplanta-
tion because of increased shear stress and wall tension
initiated by increased perfusion pressure. Nonperfused fresh
huSV showed few TLR4-positive cells in the subendothelial
longitudinal muscle layer (Figure 2A). Parallel sections of the
same fresh huSV were subjected to 4 hours of perfusion with
autologous blood on arterial pressure. These sections showed
an impressive focal increase of TLR4 expression within the
longitudinal layer (Figure 2B).
Figure 3. TLR4 expression on murine vein grafts
of hypercholesterolemic APOE*3Leiden mice was
detected by immunohistochemistry and reverse
transcription–polymerase chain reaction. Analysis
over time was done on grafts harvested at t1 (A),
3 (B), 7 (C), and 14 (D) days after surgery. Rabbit
IgG isotype control (E). Arrows indicate positive
TLR4 staining. Reverse transcription–polymerase
chain reaction of TLR4 (F) CD68 (G), and
-smooth muscle actin (H) mRNA was performed
at t0 hours, 6 hours, and 1, 3, 7, and 28 days
after surgery. A Student t test was used for statis-
tical analysis; *P0.05 compared with t0.
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TLR4 Expression in Murine Vein Grafts
During Remodeling
As the findings presented above indicate an increase of TLR4
presence during huSV remodeling, TLR4 presence on the
protein and mRNA level was analyzed during remodeling in
mice. Therefore, a murine vein graft model was used that
represents human vein graft thickening and accelerated ath-
erosclerosis. TLR4 protein presence was studied by immuno-
histochemistry during progression of remodeling over time in
hypercholesterolemic APOE*3Leiden mice. A marked ex-
pression of TLR4 was detectable in these vein grafts. In the
early remodeling phase, when the graft was only 1 or 2 cell
layers thick, TLR4-positive spots were observed (Figure 3A
and 3B). At t7 and t14 days, vessel wall thickness has
increased markedly. Within these segments, focal areas of
intense TLR4 protein expression could be detected (Figure
3C and 3D). Rabbit IgG isotype control showed no staining
(Figure 3E). Expression of TLR4 mRNA during remodeling
was detected by reverse transcription–polymerase chain re-
action in hypercholesterolemic APOE*3Leiden mice over
time at t0 hours, 6 hours, and 1, 3, 7, and 28 days after graft
placement. A rapid increase in TLR4 mRNA could be
detected in the early remodeling phase. During intermediate
and late-phase remodeling, TLR4 mRNA remained upregu-
lated (Figure 3F) (t0 versus 6 hours, P0.03; t0 versus 1
day, P0.0039; t0 versus 3 days, P0.02; t0 versus 7
days, P0.1; t0 versus 28 days, P0.09). The increase of
TLR4 expression may be partly related to an influx of 68
cells (t0 versus 6 hours, P0.6; t0 versus 1 day,
P0.0037; t0 versus 3 days, P0.0026; t0 versus 7 days,
P0.0032; t0 versus 28 days, P0.0003) during remodel-
ing and proliferation/migration of SMC (t0 versus 6 hours,
P0.07; t0 versus 1 day, P0.0007; t0 versus 3 days,
P0.17; t0 versus 7 days, P0.02; t0 versus 28 days, P
0.006; Figure 3G and 3H).
Presence of Endogenous TLR4 Ligands in Murine
Vein Grafts
Remodeled grafts have been subjected to proliferation, mi-
gration, and turnover of cells and matrix components. These
processes may cause an upregulation of DAMPs that can be
recognized by TLR4. We localized several of these DAMPS
in vein grafts of hypercholesterolemic APOE*3Leiden mice
harvested at t14 days. Proteins in response to cellular stress,
such as HSP60 and high-mobility group box 1 (HMGB1), are
known TLR4 ligands. The presence of HSP60 was detected,
especially in the subendothelial layer of the thickened vessel
wall (Figure 4A). HMGB1, normally at rest inside the
nucleus, was now detected in the cytoplasm, where it is
known to act in a cytokine-like way (Figure 4B).24 In
addition, matrix components that are expressed during matrix
turnover were studied. The glycoprotein tenascin-C was
demonstrated, especially at the matrix-rich adventitial site of
the graft but also near the luminal site in matrix-containing
areas (Figure 4C). These endogenous ligands could poten-
tially colocalize with TLR4 because they were present in the
lesion site and in areas that also express TLR4 at the same
time point (Figures 3D, 4A, 4B, and 4C). Furthermore,
mRNA expression of the matrix component biglycan, which
may function as a TLR4 ligand, was studied over time, and a
more than 10-fold increase of mRNA was detectable after 7
days. This increase in biglycan expression remained upregulated
during the remodeling process (t0 versus 6 hours, P0.25;
t0 versus 1 day, P0.017; t0 versus 3 days, P0.21; t0
versus 7 days, P0.004; t0 versus 28 days, P0.021;
Figure 4D).
Functional Role of TLR4 in Murine Vein
Graft Remodeling
To explore whether TLR4 has a functional role in vein graft
thickening, an essential step in VGD leading to vein graft
failure, a venous interposition was placed in the carotid artery
of Balb/c (n8) and TLR4-deficient (C3H-Tlr4LPS-d) mice
(n7). C3H-Tlr4LPS-d mice showed 4812% (0.2640.06
versus 0.1360.02 mm2, P0.04) less wall thickening than
Balb/c controls (Figure 5A). Graft patency was kept by
compensatory outward remodeling in the Balb/c mice, indi-
cated by a significantly larger total vessel wall area
(0.600.03 versus 0.420.05 mm2, P0.01) (Figure 5B),
Figure 4. Endogenous TLR4 ligands were
detected in vein grafts of hypercholesterolemic
APOE*3Leiden mice. The presence of HSP60 (A),
HMGB1 (B), and tenascin-C (C) was detected by
immunohistochemistry in vein grafts 14 days after
surgery. Reverse transcription–polymerase chain
reaction on matrix component biglycan mRNA was
performed at t0 hours, 6 hours, and 1, 3, 7, and
28 days after surgery (n3 to 4 per time point) (D).
A Student t test was used for statistical analysis;
*P0.05 compared with t0.
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thereby creating only a small difference in the ratio of
lumen to total vessel wall area (Supplemental Figure I).
Furthermore, the reduced vessel wall thickening correlated
with a reduced -SMC-actin positive area in the C3H-
Tlr4LPS-d mice (0.0220.003 versus 0.0470.009 mm2,
P0.035) (Figure 5C).
TLR4 Silencing In Vitro
To create a tool for local TLR4 gene silencing, 5 lentiviral-
based shRNAs were produced and validated by measurement
of murine TLR4/MD2 expression on Chinese hamster ovar-
ian cancer cells by fluorescence-activated cell sorting analy-
sis, and the best vector was selected (not shown). The selected
vector showed a dose-dependent downregulation of TLR4
protein expression (Supplemental Figure II). Murine 3T3
fibroblasts were then transduced by selected lenti-shTLR4
(TRCN0000065787), lenti-control, or PBS and subsequently
stimulated with different proinflammatory stimuli to obtain
insight on its specificity in reducing TLR4 induced nuclear
factor-B (NF-B) activation. Lenti-shTLR4 gave a signifi-
cant reduction in NF-B activation after administration of
TLR4 ligand LPS (P0.01). Application of Pam3Cys, tumor
necrosis factor-, or interleukin-1 had no different effect on
NF-B activation compared with the controls (Supplemental
Figure III).
Local TLR4 Silencing in Hypercholesterolemic
APOE*3Leiden Mice
To validate the potential of TLR4 as a local therapeutic in
VGD, a study was pursued using local TLR4 gene silencing
to diminish VGD in APOE*3Leiden mice. These mice, when
fed a high-cholesterolemic diet, are well known to develop
massive VGD because of neointima formation and acceler-
ated atherosclerosis. After graft placement in APOE*3Leiden
mice pluronic gel with PBS (n8), lenti-control (n9) or
lenti-shTLR4 (n7) was lubricated around the graft. Mice
were fed a Western-type diet for the total duration of the
experiment, starting 3 weeks before surgery. No significant
differences between groups in cholesterol level (PBS
9.60.9 mmol/L, lenti-control 9.71.0 mmol/L, and lenti-
shTLR4 10.20.6 mmol/L) or body weight were observed
(not shown).
Local gene silencing of TLR4 led to a 4413% reduction
of vessel wall thickening in the graft segment (PBS, 0.40
0.04 mm2; lenti-control, 0.420.04 mm2; lenti-shTLR4,
0.230.03 mm2) (PBS versus lenti-shTLR4, P0.0059;
lenti-control versus lenti-shTLR4, P0.0052; PBS versus
lenti-control, P0.96). A difference in total vessel wall area
was found only between lenti-control and lenti-shTLR4. In
addition, a beneficial lumen/total cross-section ratio showed a
beneficial outcome for the lenti-shTLR4–treated group (PBS,
0.450.05 mm2; lenti-control, 0.540.04 mm2; lenti-
shTLR4, 0.700.03 mm2) (PBS versus lenti-shTLR4,
P0.0012; lenti-control versus lenti-shTLR4, P0.0079;
PBS versus lenti-control, P0.14) (Figure 6A to 6D). Fur-
thermore, although quantitative interpretation of immunohis-
tochemistry has to be done with extreme caution, treatment
with lenti-shTLR4 gave a reduction in focal TLR4 expression
in the graft (Figure 6E). After TLR4 silencing in the vein
grafts of APOE*3Leiden mice, the areas positive for macro-
phages (MAC3-positive area) and SMC (-SMC-actin–pos-
itive area) were reduced by 54% and 61%, respectively,
compared with the PBS group. (Details are given in Supple-
mental Table I.)
Discussion
The present study describes the role of TLR4 in vein graft
remodeling in humans and mice with a profound presence of
TLR4, endogenous TLR4 ligands during remodeling, and the
therapeutic potential for local TLR4 silencing. Abundant
TLR4 presence was noticed in freshly isolated huSV. In
addition, in remodeled areas of fresh huSV, in fresh huSV
Figure 5. Vein graft remodeling in Balb/c and C3H-Tlr4LPS-d
mice (Balb/c, n8; C3H-Tlr4LPS-d, n7). Areas of vein graft sec-
tions were quantified by using 6 sequential sections per vein
graft of each mouse. A mean of these 6 sections was used as
the outcome of vein graft remodeling per mouse. Outcomes of
analysis are expressed in millimeters squared (meanSEM).
C3H-Tlr4LPS-d mice showed a significant reduction in vein graft
wall thickening compared with Balb/c controls (A). C3H-Tlr4LPS-d
mice showed a significantly smaller total vessel wall area (B).
The total of positive -SMC actin area was significantly smaller
in C3H-Tlr4LPS-d mice (C). Shown are representative
hematoxylin-phloxin-saphron (HPS)-stained sections of Balb/c
and C3H-Tlr4LPS-d vein grafts (D). *P0.05. Statistical analysis
was performed by use of a Mann-Whitney test.
Karper et al TLR4 in Vein Graft Disease 1037
 at Vrije Universiteit--Amsterdam on July 11, 2011http://atvb.ahajournals.org/Downloaded from 
after reperfusion, and in coronary vein grafts derived at
autopsy, an upregulation of TLR4 protein was observed. In
murine vein grafts of hypercholesterolemic APOE*3Leiden
mice, TLR4 expression is present over time at the protein and
mRNA levels, and a series of endogenous TLR4 ligands,
HSP60, HMGB1, tenascin C, and biglycan was expressed.
Furthermore, TLR4-deficient mice show a significant reduc-
tion in vein graft thickening and less outward remodeling
after vein grafting. Moreover, local gene silencing of TLR4
gives a clear reduction in vein graft thickening and a
beneficial lumen/total cross-section area ratio.
Nowadays, TLR4 is considered to be an important factor in
inflammatory-mediated diseases. VGD is strongly mediated
by remodeling initiated by wall stress, cell damage, and
inflammation. The level of TLR4 expression may vary among
different vessel specimens and is dependent on activation and
local environmental changes, such as wall stress, cell damage,
and inflammation.17 Furthermore, these differences may also
be relevant for the presence and levels of endogenous TLR4
ligands. Therefore, it is of major importance to evaluate
TLR4 expression, function, and therapeutic potential in a
VGD-related setting. Here, we report the presence of TLR4
on the circular muscle layer of fresh huSV and a rapid
increase of focal TLR4 expression within 4 hours of reper-
fusion in an extracorporeal circulation set up with arterial
pressure on sections of fresh huSV. Increased TLR4 expres-
sion may be initiated by damage-inducing processes, such as
ischemia/reperfusion and increased wall tension/shear stress
due to pressure and flow disturbances.25,26 In addition, the
initiated damage to the vessel contributes, most likely by
inducing the release of endogenous ligands, to the prolif-
eration and migration of VSMC and the influx of inflam-
matory cells, such as macrophages, resulting in thickening
of the vessel wall. These cells, which play an important role
in vascular remodeling, have been shown to express
TLR4.13,18,27,28 In support of this, we noticed an abundant
Figure 6. Vein graft remodeling after local TLR4 silencing in hypercholesterolemic APOE*3Leiden mice (PBS, n8; lenti-control, n9;
lenti-shTLR4, n7). Areas of vein graft sections were quantified by using 6 sequential sections per vein graft vein graft of each mouse.
A mean of these 6 sections was used as the outcome of vein graft remodeling per mouse. Outcomes of analysis are expressed in milli-
meters squared (meanSEM). Vein graft wall thickening was reduced in the lenti-shTLR4 treated group compared with the controls (A).
Total vessel wall area was smaller in the lenti-shTLR4 group compared with the lenti-control (B). A beneficial lumen/total cross-section
area ratio was observed in the lenti-shTLR4 treated group (C). Shown are representative hematoxylin-phloxin-saphron (HPS)-stained
sections of focal vein graft wall thickening (D). Focal TLR4 expression is shown in vein grafts locally treated with PBS (left), lenti-control
(middle), and lenti-shTLR4 (right) (E). *P0.01. Statistical analysis was performed with a 1-way ANOVA.
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TLR4 presence within the thickened vessel wall of severely
remodeled areas in vein grafts of human and mouse origin.
Previously, localization of TLR4 has been shown in remod-
eled arteries during atherogenesis and after angioplasty, and
the presence of TLR4 ligands may alter its expression.13,14,16
The discovery that these TLR4 ligands can be of endoge-
nous origin further emphasizes the importance of TLR4 in
inflammatory-mediated diseases.3 The endogenous ligands,
most often referred as DAMPs, are most often danger signals
or degradation products of matrix component that become
available in response to injury. Bypass surgery itself and the
subjection of the transplanted vessel to hypoxia and increased
blood pressure can cause a release of powerful inducers of
cellular stress and tissue damage. The observed presence of
HSP60, extracellular high mobility group box 1 (HMGB1),
tenascin-C, and upregulation of biglycan mRNA during
remodeling is a good example of this. Previously, Hochleitner
et al described the release of HSP60 after shear stress,29 and
others showed the capability of HSP60 to bind directly to
TLR4, thereby initiating proliferation of VSMC.30 Cellular
stress may also cause passive release of HMGB1 by a variety
of cell types, including endothelium and monocytes/macro-
phages, and acts as a cytokine capable of binding to TLR4,
thereby initiating a proinflammatory response.8,31,32 Matrix
turnover importantly mediates vein graft remodeling. The
extracellular matrix glycoprotein tenascin-C is related to
tissue repair and injury. Normally, tenascin-C is not present
in huSV, but after graft placement, its expression is signifi-
cantly increased in huSV grafts.33,34 If present, it is capable of
promoting SMC migration35 and growth36 and affecting
important genes in vascular remodeling. Recently, tenascin-C
was found to be an endogenous TLR4 ligand without the need
for CD14 or MD-2 as accessory molecules for signal trans-
duction, and therefore tenascin-C may act in vein grafts also
via TLR4 signaling.37 The matrix component biglycan is
coimmunoprecipitated with TLR4, and by signaling via
TLR4 on macrophages it has a proinflammatory effect.
Moreover, it enhances SMC proliferation.36,38 The observed
increase in biglycan expression over time in the vein graft
points toward an increased TLR4 signaling in murine vein
grafts with biglycan as ligand.
The reduced vein graft wall thickening in the C3H-
Tlr4LPS-d mice by reducing total SMC amount demonstrates
that not only are TLR4 and its endogenous ligands expressed
in the remodeling vein graft segments but TLR4 is also
causally involved in vein graft remodeling.
The current results indicate the presence and even causal
involvement of TLR4 and the upregulation of multiple
endogenous ligands in VGD; therefore, several new targets
can be proposed for therapeutic interference. Long-term
systemic antiinflammatory treatment against TLR4 would be
difficult and undesirable because of the expected adverse side
effects. Furthermore, targeting of a single DAMP would be
not a good option because multiple DAMPs are upregulated
and are able to trigger TLR4 signaling involved in vascular
remodeling, making it difficult to select them as therapeutic
targets individually. Local RNA interference for TLR4 may
overcome this problem. shRNA constructs are able to inhibit
gene translation into protein, thereby initiating effective gene
silencing.39,40 Previously, our group showed that local graft
transduction using a lentivirus can be performed efficiently in
vivo.41 In support, others have shown encouraging results for
the applicability of local gene therapy.42,43
Therefore, local lentiviral infection with the selected TLR4
shRNA was performed in vein grafts positioned in the carotid
artery of hypercholesterolemic APOE*3Leiden mice. The
specificity of the shRNA construct used was demonstrated by
its capacity to decrease murine TLR4 expression on trans-
formed Chinese hamster ovarian cancer cells and to reduce
NF-B activation in murine fibroblasts after LPS activation.
NF-B activation after challenging the cells with stimuli
other than the TLR4 ligand LPS, such as Pam3Cys, tumor
necrosis factor-, or interleukin-1b, was not affected, dem-
onstrating the specificity of the construct.
Morphometric analysis after silencing of TLR4 demon-
strated a reduction in vessel wall thickening, which was
supported by a focal decrease in TLR4 expression and a
reduction in the total number of macrophages in the lesions.
As in the TLR4-deficient mice, reduction of total SMC in the
lenti-shTLR4 treated group correlated with the decrease in
vessel wall thickening. Furthermore, local TLR4 silencing
increases the ratio of lumen versus total cross-sectional area.
This indicates a beneficial effect of local TLR4 silencing on
vein graft remodeling, with effects on graft patency in the
long term.
This also might have significance for the treatment of
patients because vein grafts can readily be treated locally ex
vivo during surgery, thus presenting a unique opportunity for
gene transfer or gene inhibition to alter the remodeling
response.
In summary, upregulation of TLR4 expression (in both
human and mouse), as well as its endogenous ligands, in vein
grafts during graft remodeling and the reduced vein graft
thickening in TLR4-deficient C3H-Tlr4LPS-d mice point out the
important involvement of TLR4 and its endogenous ligands in
VGD. Furthermore, the reduction of vein graft vessel wall
thickening in hypercholesterolemic APOE*3Leiden mice after
local lentiviral shRNA-mediated interference in the TLR4 path-
way indicate the potential of TLR4 as a local therapeutic target
to improve vein graft survival.
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 Supplement Material 
 
Materials and Methods 
Mice 
All animal experiments were approved by the animal welfare committee of our institute. 
10 week old male Balb/c, C3H-Tlr4LPS-d and APOE*3Leiden mice, bred in our laboratory, 
were used. C3H-Tlr4LPS-d mice have a Balb/c background but carry a mutation that causes 
a deficiency in TLR4 signaling. 
APOE*3Leiden were fed a western-type diet (Arie Blok, The Netherlands), starting 3 
weeks before surgery and continued during the experiment to develop a diet dependent 
hypercholesterolemia.  
All mice received water and food ad libitum. One week before surgery cholesterol levels 
in serum were determined (Roche Diagnostics, The Netherlands).  
Production of lentiviral shRNA against TLR4 
Out of the “Mission Library” (Sigma Aldrich, The Netherlands) 5 sequence-verified short 
hairpin RNA (shRNA) lentiviral-plasmids against TLR4 were isolated and produced. 
Lentiviral packaging vectors (pCMV-VSVG, pMDLg-RREgag/pol, pRSV-REV) and 
transfer vector (pLKO.1-puro Vector) were co-transfected in HEK293T cells using 
calcium-phosphate precipitation method. Lentiviral particles were concentrated using 
sucrose cushion centrifugation (30.000rpm, 2h). Quantification of lentiviral titer was 
done by p24 ELISA (ZeptoMetrix, USA).  
The vectors encoded the shRNAs sequences against TLR4 (lenti-shTLR4) as indicated: 
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TRCN0000065783  NM_021297.1-3054s1c1 
TRCN0000065784  NM_021297.1-1246s1c1  
TRCN0000065785  NM_021297.1-1568s1c1 
TRCN0000065786  NM_021297.1-509s1c1 
*  TRCN0000065787  NM_021297.1-2247s1c1 
* Selected and in vivo applied lenti-shTLR4  
In vitro targeting of murine TLR4 expression  
CHO cells expressing murine TLR4/MD2 and control cells (kindly provided by Dr. A. 
Garritsen, Merck Sharp Dome, The Netherlands) were transduced with the 5 different 
lentiviral based shRNAs in a 0.1:1, 0.5:1, 1:1 and 2:1 ratio (lentiviral particles/cells) in 
DMEM (Invitrogen, The Netherlands) containing 0.8ug/ml polybrene (Sigma Aldrich, 
The Netherlands) with 5% Fetal Calf Serum. After overnight transduction medium was 
replaced by fresh medium. Subsequent TLR4 expression was measured by FACS 
analysis with a TLR4-MD2 FITC antibody (HyCult biotechnology, The Netherlands) 
after 5d. 
 
Transduction of murine 3T3 fibroblasts: 
NIH 3T3 mouse fibroblasts stably transfected with a 5xNFκB-Luciferase vector as 
described 1. After overnight adherence, cells were transduced with, lenti-control 
(lentivirus-GFP) or lenti-shTLR4 (TRCN0000065787) per well (MOI of 7.5) or PBS. 
Medium was discarded after 4h transduction and replaced by fresh medium. Cells were 
cultured for 5d followed by stimulation with LPS, TNFα, Pam3Cys, or IL1β. After 6h 
stimulation, cells were washed with 0.9% NaCl and lysed for 15min on ice. Bright-Glo 
was added and luminescence was measured on the Lumistar Optima. 
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Murine vein graft model 
In the mouse carotid artery a venous interposition was placed as described previously2. 
Caval veins of donor mice were placed as vein grafts in the right carotid artery of 
recipient mice.  
 
Lentiviral transduction of the vein graft in situ 
Before wound closure , in the APOE*3Leiden mice, 150μl 20% pluronic gel (Sigma 
Aldrich, The Netherlands) containing 1.5*106 lentiviral particles (P24 Elisa, 
ZeptoMetrix, USA) and 0.8μg/ml DEAE (Sigma Aldrich, The Netherlands) was 
lubricated around the graft.   
 
Vein graft thickening quantification  
Mice were sacrificed 28d (or as stated otherwise) after surgery for histological analysis. 
Vein graft segments were harvested after perfusion fixation with 4% formaldehyde, 
fixated overnight and paraffin-embedded using an automated tissue processor (Leica, 
Germany). Cross-sections were made throughout the embedded vein grafts. Six 
representative sections per vessel segment were stained with Haematoxylin-Phloxine-
Saffron (HPS) for histological and morphometric analysis (Leica, Germany). Vein graft 
thickening was defined as the area between lumen and adventitia and determined by 
subtracting the luminal area from the total vessel wall area.  
 
Human vein graft tissue 
Veins were surplus segments of huSVs that were collected in the operating room from 
patients undergoing coronary artery bypass grafting (CABG). Vessel specimens were 
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freshly collected under sterile conditions. One part of the segment was directly fixated for 
histopathological examination and another part was perfused on an extracorporeal 
perfusion circuit connected to the heart-lung machine during the CABG procedure with 
autologous blood and under arterial pressure (60mmHg) as described by Stooker3. The 
study was approved by the local ethics committee. Patients were included in the study 
after providing informed consent. Non-perfused fresh huSV segments (n=6 patients) and 
parallel fresh huSV segments that were perfused for 4h respectively (n=6 patients) were 
analyzed huSV segments that have served as coronary bypass for more than 5yrs (n=5 
patients) were derived at autopsy. Use of patient material after completion of the 
diagnostic process is part of the patient contract in the VU University Medical Centre. 
Immunohistochemistry                   
Paraffin embedded sections (5µm) were deparaffinized in xylene. Peroxidase activity was 
blocked by incubation in 0.3% (v/v) H2O2 in methanol for 20min. Antigen retrieval was 
performed and tissue sections were pre-incubated with 5% bovine serum albumin (BSA), 
followed by incubation with detecting antibody. 
TLR4 presence was stained with TLR4 antibody (sc-10741 rabbit anti-human, Santa 
Cruz, United States)4, HSP60 (rabbit anti-mouse, Abcam, UK), HMGB1 (rabbit anti-
mouse Abcam, UK), Tenascin C (rabbit anti-mouse, Millipore, USA), SMCs with α-
smooth muscle cell actin staining (Roche Applied Biosciences, Germany) and 
macrophages with MAC3ab (BD Pharmigen, USA). 
After washing in PBS, sections were incubated for 1h with a secondary antibody (Donkey 
anti-Rabbit, GE Healthcare, USA), washed in PBS, incubated for 1h with AB complex 
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(Vector laboratories, The Netherlands) and visualized with Novared (Vector laboratories) 
or DAB (Dako, Denmark). Slides were counterstained with haematoxylin. 
Immunopositive areas of SMC and macrophages were calculated as percentage of total 
vein graft area in cross-sections by morphometry (Leica, Germany). To increase the 
TLR4 detection after AB complex slides were incubated for 10 minutes with biotinylated 
thyramids and again 1h with ABcomplex prior to visualization with Novared.  
As control parallel sections were incubated with 1% PBS/BSA alone or with Rabbit IgG 
isotype without adding detecting antibodies. Controls were all negative (not shown). 
 
RT-PCR: 
 
Total RNA was isolated using Tri-Reagent (Sigma-Aldrich) according to the 
manufacturer's protocol. The expression levels of TLR4 and Biglycan were analyzed by 
RT-PCR (real time polymerase chain reaction). The relative mRNA expression levels 
were determined by using GAPDH as house keeping gene and the 2[−ΔΔC(T)] method. 
Values were expressed as fold of respective controls. 
 
Statistical analysis 
Values are presented as mean±standard error of the mean (SEM). Statistical significance 
was calculated in SPSS for Windows-17.0. Differences between groups were determined 
using a non parametric Mann-Whitney and One-way ANOVA (Kruskal-Wallis, non-
parametric Dunn’s Multiple Comparison Test) tests. A Student’s t-test was used for 
statistical analysis of in vitro assays. Probability values of less than 0.05 were considered 
statistically significant. 
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Legend online supplement  
Figure I: 
Ratio lumen/total vessel wall area of vein grafts of balb/c (n=8) and TLR4 deficient 
(C3H-Tlr4LPS-d) mice (n=7).  
Figure II:  
In vitro analysis of lenti-shTLR4 silencing. Murine TLR4 expression on CHO cells was 
analyzed after a dose dependent transduction with lenti-shTLR4. Positive control (A). 
Dose dependent transduction of lenti-shTLR4 in a 1:0.1 (B) 1:0.5 (C) 1:1 (D) 1:2 
lentiviral particles/cells ratio showed a profound dose dependent reduction of TLR4 
expression (E).  
Figure III:  
Murine 3T3 fibroblast were transduced with PBS, lenti-control or lenti-shTLR4 and 
subsequently stimulated with LPS, 100ng/ml; Pam3Cys, 10µg/ml; TNF-α, 10ng/ml; IL-
1β, 10ng/ml; Non Stimulated. NFkB activation due to LPS stimulation was significantly 
reduced in the lenti-shTLR4 transduced fibroblasts (F), A students t-test was used for 
statistical analysis * = P<0.01.  
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Tabel I:  
 PBS Lenti-control Lenti-shTLR4 
Macrophages 40653m2 * 44687m2 18764m2 
SMC 1289120m2 * 515169m2 51163m2 
 
Macrophages: PBS vs. lenti-shTLR4 p=0.037, lenti-control vs. lenti-shTLR4 p=0.054, 
PBS vs. lenti-control p=1.00. SMC: PBS vs. lenti-shTLR4 p=0.00006, lenti-control vs. 
lenti-shTLR4 p=0.53, PBS vs. lenti-control p=0.0059. 
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